News

XTRAC Excimer Laser: A Revolutionary Solution for Eczema

XTRAC Excimer Laser: A Revolutionary Solution for Eczema

Understanding Eczema Awareness and Treatment Innovations

In recognition of Eczema Awareness Month, STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a leading medical technology company, showcases the compelling clinical evidence supporting the efficacy of their XTRAC Excimer Laser treatment for localized atopic dermatitis. This condition, known as one of the most prevalent forms of eczema, is affecting millions across age demographics. The excitement about this therapy peaks as the American Medical Association (AMA) expands the excimer laser applications, enabling reimbursement under various health plans.

Dr. Dolev Rafeli, the CEO of STRATA, highlights the significant advancements in excimer laser treatments that have been embraced by dermatologists for over two decades. Utilizing the XTRAC laser has become increasingly popular among healthcare providers, which demonstrates a surge in peer-reviewed publications and clinical studies attesting to its safety and effectiveness. The encouraging results have triggered an advocacy push for its inclusion in broader treatment options that cater to various skin conditions.

The Weight of Atopic Dermatitis

Atopic dermatitis impacts more than 9.6 million children and 16.5 million adults in the United States. The ongoing struggle with this chronic condition creates a significant burden, influencing not just physical health but also emotional well-being and quality of life. Patients endure severe discomfort due to symptoms like painful skin fissures and relentless itching, which can affect sleep and daily activities. Acknowledging the challenges many face, STRATA is committed to offering advanced solutions that cater to this urgent medical need.

Dr. Mark G. Lebwohl, a renowned leader in dermatologic research, acknowledges the effectiveness of the XTRAC laser, stating that it is one of the most powerful treatment options available for localized eczema. His endorsement reflects the mounting evidence from clinical studies and patient outcomes that suggest XTRAC could change the way patients experience care for this often debilitating condition.

Clinical Studies Supporting XTRAC's Efficacy

The strength of XTRAC as a treatment option is fortified by numerous clinical trials:

  • Baltás et al. (JEADV 2006) – In early trials, 15 patients showcased marked improvements in symptoms such as redness and itching after four weeks of treatment. The reduction in itching intensity was notably 81%, significantly enhancing patients' quality of life.
  • Brenninkmeijer et al. (British Journal of Dermatology 2010) – A comparative study against the standard steroid therapy demonstrated that the excimer laser not only matched but sometimes exceeded results in terms of skin improvement and longevity of effects.
  • Shroff et al. (International Journal of Dermatology 2016) – In treating chronic hand and foot eczema, patients exhibited a staggering 69% reduction in disease severity and achieved durable remission for an average of 11.3 months post-treatment.

Why the XTRAC Excimer Laser Excels in Treatment

  • Focused Treatment: The XTRAC laser targets affected skin precisely, leaving surrounding healthy tissue unharmed.
  • Efficiency in Challenging Areas: It proves particularly effective for treating hard-to-reach areas like hands and feet where topical treatments are less feasible.
  • Minimized UV Exposure: Offers a lower overall UV exposure compared to conventional phototherapy methods, providing a safer alternative.
  • Convenience: Quick treatment sessions lead to faster relief and prolonged results, enhancing patient satisfaction.
  • Steroid-Free: The therapy eliminates the need for long-term steroid use, greatly reducing potential side effects.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences stands at the forefront of medical innovations aimed at transforming dermatologic treatments. Their portfolio encompasses the XTRAC Excimer Laser and other advanced therapies like the VTRAC lamp systems. STRATA’s unique Partnership Program offers practitioners an efficient way to integrate these solutions into their practices without upfront costs, thus promoting accessibility to advanced patient care.

As research continues and new studies emerge, STRATA is poised to be a leader in dermatological advancements, reflecting the potential to redefine eczema management and patient care.

Frequently Asked Questions

What is atopic dermatitis?

Atopic dermatitis is a chronic skin condition characterized by dry, itchy, and inflamed skin, affecting millions of people worldwide.

What is the XTRAC Excimer Laser?

The XTRAC Excimer Laser is a targeted therapy that treats localized forms of atopic dermatitis and other dermatologic conditions using focused UV light.

How effective is the XTRAC laser for eczema?

Clinical studies have shown that many patients experience significant symptom relief and improved skin condition after XTRAC treatment.

Are there any side effects of using the XTRAC laser?

Most patients tolerate the treatment well, experiencing only mild side effects similar to sunburn.

How can I access treatment with STRATA Skin Sciences' products?

STRATA offers partnerships with healthcare providers, making it easier for practices to administer XTRAC treatment without high initial costs.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

WellBe Taps New Tech Chief to Elevate Home Care

Updated Category News Views 7

In a move that's got the healthcare world buzzing, WellBe Senior Medical just brought in a heavyweight to steer its digital ship. They've appointed Jeffrey Brown as their new Chief Digital & Information Officer. What's shaking? Brown's stepping into the ring to tackle the age-old healthcare dilemma: making tech work smarter, not harder, especially at home. From High-Tech...

Continue Reading
Advocacy for Hiring Disabled Kidney Patients Gains Steam

Updated Category News Views 4

Making Jobs Accessible for Kidney Patients Well, things are stirring up on Capitol Hill, and it's high time, if you ask me. The American Association of Kidney Patients (AAKP) is rallying hard for a bipartisan bill that could change the landscape for folks grappling with kidney diseases and disabilities. You’ve got Reps Pete Sessions and Steny Hoyer pushing this American...

Continue Reading
Hyperliquid Expands Stock Buyback to $100 Million

Updated Category News Views 34

Diving Into Hyperliquid's $100 Million Bold Move Let’s cut through the corporate fluff—Hyperliquid Strategies Inc. just cranked up their stock repurchase program to a cool $100 million. Yep, that’s right—the brain trust behind NASDAQ:PURR has pulled out the checkbook to buy more of its own shares. This decision, unveiled on October 23, 2026, is like tossing a...

Continue Reading
Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Updated Category News Views 71

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Continue Reading
Parents Nationwide Rally for Youth Online Safety Imperative

Updated Category News Views 14

Ringing the Alarm on Digital Dangers Like trying to herd cats on a wild day at the market, keeping teens safe online is a task as tricky as they come. And now, with over 20,000 parents joining forces, it seems there's a real demand out there for some much-needed consistency in online safeguards across all social media platforms. This isn't just about one platform or...

Continue Reading
Monterey Desalination Project: Costs, Challenges & Future

Updated Category News Views 19

Water Woes Dragging on in Monterey? Alright, let's dive into the nitty-gritty of this water supply saga in the Monterey Peninsula. If you're wondering why California American Water is hustling so hard, it's because the taps around here ain't running like they should. This mess has been stretching on for ages, with everyone thirsty for a sustainable answer. The Cost of...

Continue Reading
Rural Hospitals Face Shaky Future; Warbird RCM Steps In

Updated Category News Views 26

Revamping Revenue Cycle Management for Rural Healthcare In a world that's increasingly teetering on the delicate tightrope of balance sheets, Warbird Healthcare Advisors is stepping into the ring with fists up, ready to fight for rural hospitals. Introducing their latest venture, Warbird RCM Partners, they're honing in on revenue cycle management and billing services to...

Continue Reading
Millrose Faces Securities Fraud Suit Amidst Decline

Updated Category News Views 77

Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...

Continue Reading
CapCut's AI Tools Revolutionize Visual Content Creation

Updated Category News Views 8

Riding the AI Content Creation Wave You know, once upon a time, crafting stunning visual content was a task that had creatives burning the midnight oil. But these days, it seems like artificial intelligence is shaking things up—and CapCut's sitting pretty at the helm of this revolution. Recently, Consumer365 gave CapCut a nod as a top contender for visual content...

Continue Reading
New Cancer Center to Transform Rural Florida Care

Updated Category News Views 9

If you think living in a rural area means settling for second best when it comes to healthcare, Tampa General Hospital's got news for you. A brand-new cancer center is sprouting up in Loxahatchee—aimed squarely at providing top-tier cancer care to Florida's Glades region, where communities often get the short end of the stick when it comes to healthcare access. And...

Continue Reading

Top 5 Most Recently Viewed Articles

KKR Expands Tender Offer Period for FUJI SOFT Shares

Updated Category News Views 289

KKR Extends Tender Offer for FUJI SOFT KKR, renowned as a major global investment firm, has made headlines by announcing an extension to its second tender offer for FUJI SOFT INCORPORATED. This extension aims to cater to the evolving dynamics surrounding shareholder interests and market uncertainties. KKR's tender offer, which involves common shares and share options of...

Continue Reading
TFI International Announces Exciting Quarterly Dividend Plan

Updated Category News Views 134

TFI International Declares Quarterly Dividend MONTREAL — TFI International Inc. (NYSE and TSX: TFII), a leading player in the transportation and logistics sector across North America, has officially declared a quarterly dividend of US $0.45 for every share of its outstanding common stock. This dividend is set to be payable on an announced date to shareholders who are on...

Continue Reading
Exciting Growth Forecast for Lice Treatment Market Ahead

Updated Category News Views 151

Lice Treatment Market Overview The lice treatment market is experiencing significant growth, expected to reach a valuation of USD 1.75 billion by the end of the decade. The upward trajectory is primarily driven by increasing awareness regarding effective and non-toxic treatment options aimed at managing lice infestations, which predominantly affect children. The demand...

Continue Reading
BOSS Money Enhances Global Remittance with New Services

Updated Category News Views 308

BOSS Money Enhances Global Remittance with New Services BOSS Money, a leading remittance service brand, has announced exciting expansions to its offerings. The latest update allows customers to send money directly to multiple countries, including Venezuela, Brazil, and Eritrea, enhancing access for families and friends worldwide. Seamless Transfers to Venezuela Customers...

Continue Reading
ProVen VCT Expands 2025/2026 Subscription Offer Details

Updated Category News Views 303

ProVen VCT Announces Extended Offer for 2025/2026 Exciting news from ProVen VCT plc and ProVen Growth and Income VCT plc! Recently, these companies revealed an updated timeline for their subscription offers, aimed at raising substantial funds through new ordinary shares. Initially launched in November 2024, the offer was set to generate up to £30.0 million collectively,...

Continue Reading